Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program

Apr 26, 2022 10:25 AM ET

Campaign: Corporate Social Responsibility

"Gilead is proud to support this work, which builds on our existing efforts to ensure that greater inclusion and diversity are embedded into the design of clinical trials and to put the needs of patients first."

Today we announced our support of the Robert A. Winn Diversity in Clinical Trials Award Program, a five-year initiative launched by the Bristol Myers Squibb Foundation to increase diversity in clinical trials.

Read more about the program and its goal of helping enhance the development of therapeutics for all populations.

View original content here.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead Website

Gilead Sciences Announces Support for the Robert A. Winn Diversity in Clinical Trials Award Program

More from Gilead Sciences

Gilead Helps Pen a Children’s Book for Families Facing Breast Cancer

Gilead Foundation’s Healthcare Education, Access and Leadership (HEAL) Initiative Is Dedicating $5 Million to Help Build a More Diverse Bay Area Healthcare Workforce

Gilead Oncology Grant Supports 22 U.S. Organizations With $3.15 Million to Provide Support to Those Affected By Breast Cancer

Gilead Sciences: New Report Shows Every Country in the World Must Do More To End the HIV Epidemic

Championing HIV Services for LGBTQ+ Youth

Working to Build Next-Generation Cancer Therapies

Helping End HIV - Gilead Sciences

Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company